At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 180 enrolled
Drug / intervention
Tremelimumab +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase II Randomized Study of Durvalumab and Tremelimumab and Best Supportive Care vs Best Supportive Care Alone in Patients With Advanced Colorectal Adenocarcinoma Refractory to Standard Therapies
In Brief
A Phase 2 clinical trial evaluating Tremelimumab, Durvalumab, and 1 other intervention for Colorectal Cancer. Completed, enrolled 180 participants across 25 sites.
Detailed Summary
The standard or usual treatment for this disease is treatment with drugs and other treatments that may help to make a patient better or may improve their quality of life. This treatment is known as "best supportive care" (BSC). Although patients with best supportive care can feel better for some months, the cancer usually continues to grow.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsColorectal Cancer
CountriesCanada
CollaboratorsAstraZeneca
Timeline
Phase 2CompletedFinished
2017201820192020202120222023202420252026
First PostedAug 2016
Enrollment StartOct 2016
Primary CompletionOct 2018
Study CompletionJun 2022
TodayJul 2026
First PostedAug 17, 2016
Enrollment StartOct 12, 2016
Primary CompletionOct 18, 2018
Study CompletionJun 7, 2022
TodayJul 2, 2026
Enrollment to primary: 2.0 yearsPosted 9.9 years ago
Interventions
Tremelimumabdrug
Durvalumabdrug
Best Supportive Careother